Ovarian cancer
Oncology· 5 reviewed drugs· 6707 cited findings behind them
What the regulatory reviews cover
This page provides an overview of drugs whose regulatory review documents for ovarian cancer are available in this library. These drugs include Avastin, Lynparza, Elahere, Zejula, and Zolsketil pegylated liposomal. The reported outcomes vary across different trials and include measures such as overall survival, progression-free survival, and objective response rates.
For instance, Avastin was reviewed for first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer, with an Overall Survival (OS) Hazard Ratio of 0.58. Lynparza, indicated for advanced ovarian cancer in patients with deleterious or suspected deleterious germline BRCA-mutated, showed a Hazard Ratio for rPFS (BRCAm subgroup) of 0.24. Elahere, for the treatment of ovarian cancer, reported a pooled Objective Response Rate (ORR) of 13.8%. Zejula, for maintenance treatment of platinum sensitive relapsed high grade serous epithelial ovarian cancer, demonstrated a Tumour regression rate in orthotopic high-grade serous ovarian cancer PDX models (HRD positive models) of 44 %. Zolsketil pegylated liposomal, for advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen, reported 6 Grade 5 AEs (death related to AE). It is important to note that these figures are derived from different studies and are not directly comparable head-to-head.
The drugs — one cited result each
| Avastin Roche Holding AG | Overall Survival (OS) Hazard Ratio: 0.58 GENENTECH — Avastin FDA Review (NDA/BLA 125085, 2023), p.71 |
| Lynparza AstraZeneca PLC | Hazard Ratio for rPFS (BRCAm subgroup): 0.24 AstraZeneca PLC — Lynparza FDA Review (NDA/BLA 208558, 2025), p.86 |
| Elahere AbbVie Inc. | pooled Objective Response Rate (ORR): 13.8% AbbVie Inc. — Elahere EMA EPAR public assessment report (EME, p.16 |
| Zejula GSK plc | Tumour regression rate in orthotopic high-grade serous ovarian cancer PDX models (HRD positive models): 44 % GSK plc — Zejula EMA EPAR public assessment report, p.22 |
| Zolsketil pegylated liposomal Accord S L U | Grade 5 AEs (death related to AE): 6 Accord S L U — Zolsketil pegylated liposomal EMA EPAR public, p.41 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.